OPEN
2025 Catalyst Grants COPD, ILD
Submission deadline: November 6, 2024 at 16:00 EST
About the award
The COPD Catalyst Grant for Early Career Investigators competition promotes innovative research related to the diagnosis, treatment, and/or mechanism of disease for COPD.
Proposals should be creative and with the potential to benefit people living with this lung disease. The scope of the research proposal is restricted to lung disease, lung biology, and respiratory health.
Catalyst grants are scalable research projects that can include pilot studies, feasibility studies, or translational studies. Research projects must be new and not the continuation of an existing project.
Although the long-term goals for a project may extend beyond the means and timeline of this grant, the results of Catalyst projects should enable the development of funding proposals that are eligible for submission to national or international peer-reviewed competitions within 1 year after the end of the Catalyst grant.
Value
- The total funding amount available for the 2025 competition to $30,000.
- The funding is for one year and is non-renewable.
- We anticipate that three (3) grants will be offered.
Eligibility
- The nominated principal applicant, who is the principal investigator, must hold a faculty appointment at a Canadian university at the time the application is submitted.
- The nominated principal applicant must be an Early Career Investigators (ECIs). An ECI is defined as a researcher who has held an independent research appointment for a period of 0 to 60 months at the competition deadline date (first academic appointment must be after November 6th, 2019).
- Applications will be considered for research proposals related to the diagnosis, treatment, and/or mechanism of disease for people living with COPD. Applications deemed outside these areas will be eliminated from the competition.
- Research projects must be new and not the continuation of an existing project.
- Appropriate facilities must be available for the research. An institution through which the funds will be administered also needs to be identified and this institution must be authorized to administer CIHR grant and award funds (see a list of authorized institutions at: http://cihrirsc.gc.ca/e/36374.html).
- Applicants may only submit one application as a principal investigator per competition.
- Collaborations, particularly multi-disciplinary collaborations, are highly encouraged but must be justified.
- The principal investigator and collaborator(s) are not eligible if they hold or have held funding, directly or indirectly, from the tobacco, cannabis, and/or vaping industry.
Important dates & forms
- November 6, 2024: Electronic copy of application submitted via https://www.surveymonkey.com/r/COPD_ECI by 16:00. EST
- January to March 2025: Grant review committee
- March 2025: Notification of funding
- April 1, 2025: Funding start date
- October 1, 2025: Progress report and ethics approval due
- May 31, 2026: Final report due
About the award
The Interstitial Lung Disease (ILD) Catalyst Grant for Early Career Investigators competition promotes innovative research related to the diagnosis, treatment, quality of life, mechanism of disease, and/or health care services for people living with Interstitial Lung Disease (ILD).
Proposals should be creative and with the potential to benefit people living with this lung disease. The scope of the research proposal is limited to lung and respiratory health. Catalyst grants are scalable research projects that can include pilot studies, feasibility studies, or translational studies. Research projects must be new and not the continuation of an existing project.
Although the long-term goals for a project may extend beyond the means and timeline of this grant, the results of Catalyst projects should enable the development of funding proposals that are eligible for submission to national or international peer-reviewed competitions within 1 year after the end of the Catalyst award period.
Value
- The total funding amount available for the 2025 competition to $25,000.
- The funding is for one year and is non-renewable.
- It is anticipated that one (1) award will be offered to the highest-ranking candidate chosen by the Review Committee.
Eligibility
- The nominated principal applicant, who is the principal investigator, must hold a faculty appointment at a Canadian university at the time the application is submitted.
- The nominated principal applicant must be an Early Career Investigators (ECIs). An ECI is defined as a researcher who has held an independent research appointment for a period of 0 to 60 months at the competition deadline date (first academic appointment must be after November 6th, 2019).
- Applications will be considered for research proposals related to the diagnosis, treatment, quality of life, mechanism of disease, and/or health care services for people living with ILD. Applications deemed outside these areas will be eliminated from the competition.
- Research projects must be new and not the continuation of an existing project.
- Appropriate facilities must be available for the research. An institution through which the funds will be administered also needs to be identified and this institution must be authorized to administer CIHR grant and award funds (see a list of authorized institutions at: http://cihrirsc.gc.ca/e/36374.html).
- Applicants may only submit one application as a principal investigator per competition.
- Collaborations, particularly multi-disciplinary collaborations, are highly encouraged but must be justified.
- The principal investigator and collaborator(s) are not eligible if they hold or have held funding, directly or indirectly, from the tobacco, cannabis, and/or vaping industry
Important dates & forms
- November 6, 2024: Electronic copy of application submitted via https://www.surveymonkey.com/r/ILD_Catalyst by 16:00 Eastern Standard Time.
- January to February 2025: Grant review committee
- March 2025: Notification of funding
- April 1, 2025: Funding start date
- October 1, 2025: Progress report and ethics approval due
- May 31, 2026: Final report due